Request Sample Report
Pharmaceutical CDMO Market Size and Growth
The Pharmaceutical CDMO market is experiencing rapid growth, driven by increasing outsourcing trends and demand for customized drug development solutions. The market size is projected to reach approximately $80 billion by 2025, reflecting robust expansion due to innovations in biopharmaceuticals and the need for efficient manufacturing processes amid evolving regulatory landscapes. Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Lonza
◍ Catalent
◍ Thermo Fisher Scientific
◍ Samsung Biologics
◍ Fareva
◍ WuXi AppTech
◍ WuXi Biologics
◍ Siegfried
◍ FUJIFILM Diosynth Biotechnologies
◍ Asymchem
◍ Pfizer CentreOne
◍ Delpharm
◍ Recipharm
◍ AGC Pharma Chemicals
◍ Boehringer Ingelheim
◍ Vetter
◍ Curia
◍ Aenova
The Pharmaceutical CDMO market is driven by increasing demand for outsourcing, biopharmaceutical innovations, and cost efficiency. Key players like Lonza, Catalent, and Thermo Fisher offer comprehensive services, enhancing drug development and manufacturing. Their innovations and capabilities expand market reach, boosting revenue. Select companies:
- Lonza: $5.5 billion
- Thermo Fisher: $39.2 billion
- Catalent: $3.5 billion
- WuXi AppTech: $2.6 billion.
Request Sample Report
